Chuna Manual Therapy for Cervicogenic Dizziness

Not Applicable

Completed

• Conditions: Symptoms, signs and abnormal clinical and laboratory findings, NEC

• Registration Number: KCT0002565
• Lead Sponsor: Kyung Hee University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2020-12-31
• Last Update Posted: 4 March 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 49

Inclusion Criteria

1. male or female aged between 20 and 70
2. neck pain and/or stiffness with dizziness, which is related to movement or positioning of cervical spine
3. recurring symptom of dizziness over 1 month or more
4. Dizziness Handicap Inventory (DHI) = 16 at baseline
5. Informed consent

Exclusion Criteria

1. dizziness induced by vestibular disorders (e.g., benign paroxysmal positional vertigo, peripheral vestibulopathy, Meniere disease, vestibular neuronitis)
2. dizziness induced by central nervous system (CNS) disorders (e.g., cerebellar ataxia,cerebellum infarction/hemorrhage, demyelination, vertebrobasilar insufficiency, seizure, increased intracranial pressure, Parkinson's disease, migraines)
3. dizziness induced by cardiovascular disorders (e.g., arrhythmia, heart valvular disease, anemia, orthostatic hypotension, coronary artery disease)
4. dizziness induced by active or uncontrolled disease (e.g., uncontrolled diabetes mellitus, hypertension, respiratory or endocrinological disorders)
5. dizziness induced by side effects of medications
6. severe chronic or terminal diseases (malignant cancer, tuberculosis, etc.)
7. chronic psychiatric diseases under treatment (epilepsy, depression, panic disorder, etc.)
8. conditions where CMT are forbidden (spinal tumor, acute fracture, infectious spondylopathy, congenital malformations of spine, operation history of spine within 3 months, progressive neurological damage, severe neurological symptoms, spinal fixation devices, syringomyelia, hydrocephaly)
9. treatment history within 1 week for cervicogenic dizziness (NSAIDs, steroid, herbal drug, acupuncture, manual therapy)
10. women of (suspected) pregnancy or breast-feeding
11. suspicion of alcohol and/or drug abuse
12. participation in another clinical study within 1 month
13. difficulty in communicating with the investigators
14. other reasons for ineligibility of participation

Study & Design

• Study Type: Interventional Study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change from baseline Dizziness Handicap Inventory (DHI) score at week 6

Secondary Outcome Measures

Name	Time	Method
Change from baseline Dizziness Handicap Inventory (DHI) score at week 3;Changes from baseline Mean Vertigo Score (MVS) at each measurement week;Changes from baseline Visual Analogue Scale (VAS) score at each measurement week;Changes from baseline Frequency of Dizziness score at each measurement week;Changes from baseline Pain Intensity Numerical Rating Scale (PI-NRS) score at each measurement week;Changes from baseline Neck Disability Index (NDI) score at each measurement week;Changes from baseline Cervical Range of Motion (CROM) value at each measurement week;Global Perceived Effect (GPE) score;Changes from baseline Korean version of Perceived Stress Scale (K-PSS) score at each measurement week;Changes from baseline EuroQoL Five Dimensions Questionnaire (EQ-5D) score at each measurement week;New Blinding Index (New BI)